Cargando…
Helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results
BACKGROUND: This study aimed to evaluate acute toxicity and oncological outcomes of breast cancer patients who underwent adjuvant radiotherapy (RT) with tomotherapy. MATERIALS AND METHODS: The results of 114 patients who underwent adjuvant RT with Tomotherapy device between 17.08.10–12.06.2021 in An...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Via Medica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826657/ https://www.ncbi.nlm.nih.gov/pubmed/36632291 http://dx.doi.org/10.5603/RPOR.a2022.0121 |
_version_ | 1784866904711626752 |
---|---|
author | İnan, Gonca Altınışık Aral, Ipek Pinar Arslan, Aliye Celik, Tuğba Ozkader Ozturk, Huseyin Furkan Arslan, Suheyla Aytac Tezcan, Yilmaz |
author_facet | İnan, Gonca Altınışık Aral, Ipek Pinar Arslan, Aliye Celik, Tuğba Ozkader Ozturk, Huseyin Furkan Arslan, Suheyla Aytac Tezcan, Yilmaz |
author_sort | İnan, Gonca Altınışık |
collection | PubMed |
description | BACKGROUND: This study aimed to evaluate acute toxicity and oncological outcomes of breast cancer patients who underwent adjuvant radiotherapy (RT) with tomotherapy. MATERIALS AND METHODS: The results of 114 patients who underwent adjuvant RT with Tomotherapy device between 17.08.10–12.06.2021 in Ankara Atatürk Training and Research Hospital and Ankara City Hospital were evaluated retrospectively. The primary endpoint of the study was acute adverse events, and the secondary endpoints were overall survival (OS) and disease-free survival (DFS). RESULTS: The results of 103 patients who met the inclusion criteria were analyzed. The median follow-up was 21 (range 1–125.8) months. Grade +3 esophagitis was not observed in any patient; no esophagitis was observed in 60 (58.3%) patients. Grade 3 dermatitis was observed in 3 (2.9%) patients. In addition, dermatitis was not observed in 47 (45.6%) patients. The relationship between chest wall volume and esophagitis development was statistically significant (p = 0.006; Z score: −2769). The median OS was 24.1 (range 1–128.5) and median disease-free survival was 21.1 (range 1–125.8) months. Five patients (4.9%) died and 9 patients (8.7%) relapsed. Local recurrence was observed in only 1 (1%) patient. There was a statistically significant correlation between OS and contralateral lung V20 dose [p < 0.001; Spearman Correlation Coefficient (SCC) −406) and heart mean dose (p < 0.001; SCC −370)]. There was a statically significant correlation between DFS and cN (p < 0.001); pN (p < 0.001); heart mean dose (p < 0.001; SCC −351); contralateral lung V5 dose (p = 0.041; SCC −213); contralateral lung V20 dose (p < 0.001; SCC −434). CONCLUSION: Acute toxicity results show improvement in breast cancer adjuvant radiotherapy with helical tomotherapy. |
format | Online Article Text |
id | pubmed-9826657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Via Medica |
record_format | MEDLINE/PubMed |
spelling | pubmed-98266572023-01-10 Helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results İnan, Gonca Altınışık Aral, Ipek Pinar Arslan, Aliye Celik, Tuğba Ozkader Ozturk, Huseyin Furkan Arslan, Suheyla Aytac Tezcan, Yilmaz Rep Pract Oncol Radiother Research Paper BACKGROUND: This study aimed to evaluate acute toxicity and oncological outcomes of breast cancer patients who underwent adjuvant radiotherapy (RT) with tomotherapy. MATERIALS AND METHODS: The results of 114 patients who underwent adjuvant RT with Tomotherapy device between 17.08.10–12.06.2021 in Ankara Atatürk Training and Research Hospital and Ankara City Hospital were evaluated retrospectively. The primary endpoint of the study was acute adverse events, and the secondary endpoints were overall survival (OS) and disease-free survival (DFS). RESULTS: The results of 103 patients who met the inclusion criteria were analyzed. The median follow-up was 21 (range 1–125.8) months. Grade +3 esophagitis was not observed in any patient; no esophagitis was observed in 60 (58.3%) patients. Grade 3 dermatitis was observed in 3 (2.9%) patients. In addition, dermatitis was not observed in 47 (45.6%) patients. The relationship between chest wall volume and esophagitis development was statistically significant (p = 0.006; Z score: −2769). The median OS was 24.1 (range 1–128.5) and median disease-free survival was 21.1 (range 1–125.8) months. Five patients (4.9%) died and 9 patients (8.7%) relapsed. Local recurrence was observed in only 1 (1%) patient. There was a statistically significant correlation between OS and contralateral lung V20 dose [p < 0.001; Spearman Correlation Coefficient (SCC) −406) and heart mean dose (p < 0.001; SCC −370)]. There was a statically significant correlation between DFS and cN (p < 0.001); pN (p < 0.001); heart mean dose (p < 0.001; SCC −351); contralateral lung V5 dose (p = 0.041; SCC −213); contralateral lung V20 dose (p < 0.001; SCC −434). CONCLUSION: Acute toxicity results show improvement in breast cancer adjuvant radiotherapy with helical tomotherapy. Via Medica 2022-12-29 /pmc/articles/PMC9826657/ /pubmed/36632291 http://dx.doi.org/10.5603/RPOR.a2022.0121 Text en © 2022 Greater Poland Cancer Centre https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially |
spellingShingle | Research Paper İnan, Gonca Altınışık Aral, Ipek Pinar Arslan, Aliye Celik, Tuğba Ozkader Ozturk, Huseyin Furkan Arslan, Suheyla Aytac Tezcan, Yilmaz Helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results |
title | Helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results |
title_full | Helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results |
title_fullStr | Helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results |
title_full_unstemmed | Helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results |
title_short | Helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results |
title_sort | helical tomotherapy experience in breast cancer adjuvant radiotherapy and acute toxicity results |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826657/ https://www.ncbi.nlm.nih.gov/pubmed/36632291 http://dx.doi.org/10.5603/RPOR.a2022.0121 |
work_keys_str_mv | AT inangoncaaltınısık helicaltomotherapyexperienceinbreastcanceradjuvantradiotherapyandacutetoxicityresults AT aralipekpinar helicaltomotherapyexperienceinbreastcanceradjuvantradiotherapyandacutetoxicityresults AT arslanaliye helicaltomotherapyexperienceinbreastcanceradjuvantradiotherapyandacutetoxicityresults AT celiktugbaozkader helicaltomotherapyexperienceinbreastcanceradjuvantradiotherapyandacutetoxicityresults AT ozturkhuseyinfurkan helicaltomotherapyexperienceinbreastcanceradjuvantradiotherapyandacutetoxicityresults AT arslansuheylaaytac helicaltomotherapyexperienceinbreastcanceradjuvantradiotherapyandacutetoxicityresults AT tezcanyilmaz helicaltomotherapyexperienceinbreastcanceradjuvantradiotherapyandacutetoxicityresults |